Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States.


Journal

Journal of clinical neuromuscular disease
ISSN: 1537-1611
Titre abrégé: J Clin Neuromuscul Dis
Pays: United States
ID NLM: 100887391

Informations de publication

Date de publication:
Sep 2020
Historique:
entrez: 25 8 2020
pubmed: 25 8 2020
medline: 7 7 2021
Statut: ppublish

Résumé

To compare temporal trends in clinical and health care resource utilization (HRU) outcomes in people with refractory and nonrefractory generalized myasthenia gravis (gMG). A retrospective analysis of data from adults with gMG in the Myasthenia Gravis Foundation of America Patient Registry. gMG status (ever-refractory or always nonrefractory) and clinical (Myasthenia Gravis-Activities of Daily Living [MG-ADL] scores, exacerbations) and HRU outcomes were determined from questionnaires self-completed 6-monthly for up to 4 years. The probability of each outcome was compared for the 2 groups over time. The mean MG-ADL score and the probability of experiencing each outcome were significantly greater in the ever-refractory versus nonrefractory groups during each year of follow-up. Between-group differences in time trends were statistically significant for intensive care and feeding-tube use. People who have ever had refractory gMG may have worse functional status, more exacerbations, and higher HRU than people with consistently nonrefractory disease.

Identifiants

pubmed: 32833720
doi: 10.1097/CND.0000000000000301
pii: 00131402-202009000-00002
pmc: PMC7447171
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-21

Références

Ther Clin Risk Manag. 2018 Jun 26;14:1149-1153
pubmed: 29983569
J Med Econ. 2019 Jul;22(7):691-697
pubmed: 30841772
Ther Adv Neurol Disord. 2019 Mar 01;12:1756286419832242
pubmed: 30854027
Yale J Biol Med. 2013 Jun 13;86(2):255-60
pubmed: 23766745
J Clin Epidemiol. 1990;43(1):87-91
pubmed: 2319285
J Clin Neuromuscul Dis. 2019 Jun;20(4):173-181
pubmed: 31135620
Neurology. 2016 Jul 26;87(4):419-25
pubmed: 27358333
Curr Allergy Asthma Rep. 2007 Jul;7(4):293-300
pubmed: 17547852
J Neuromuscul Dis. 2018;5(3):265-277
pubmed: 30010142
Ther Adv Neurol Disord. 2018 Jan 18;11:1756285617749134
pubmed: 29403543
Semin Neurol. 2016 Oct;36(5):419-424
pubmed: 27704496
Nat Rev Neurol. 2016 May;12(5):259-68
pubmed: 27103470
Ger Med Sci. 2016 Oct 13;14:Doc12
pubmed: 27790079
J Clin Neuromuscul Dis. 2014 Jun;15(4):167-78
pubmed: 24872217
Muscle Nerve. 2011 Nov;44(5):727-31
pubmed: 22006686
Biochem Pharmacol. 2019 Jul;165:112-125
pubmed: 30978323
Muscle Nerve. 2018 Feb 27;:
pubmed: 29486521
J Neurovirol. 2018 Jun;24(3):323-331
pubmed: 29508305
Expert Rev Neurother. 2018 Jul;18(7):573-588
pubmed: 29932785
Health Qual Life Outcomes. 2015 Aug 01;13:115
pubmed: 26232146
Neurol Clin. 2018 May;36(2):253-260
pubmed: 29655448

Auteurs

Linda Harris (L)

Health Economics & Outcomes Research, Biohaven Pharmaceuticals Inc., New Haven, CT; formerly of Global Health Economics and Outcomes Research, Alexion Pharmaceuticals, Inc., Boston, MA.

Phillip H Allman (PH)

Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL; and.

Reinee Sheffield (R)

Advanced Clinical, Deerfield, IL.

Gary Cutter (G)

Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL; and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH